BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) stock closed at 95.03 per share at the end of the most recent trading day (a -1.97% change compared to the prior day closing price) with a volume of 711.92K shares and market capitalization of 17.63B. Is a component of Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 3059 people. BioMarin Pharmaceutical Inc. CEO is Jean-Jacques Bienaime.

The one-year performance of BioMarin Pharmaceutical Inc. stock is 29.08%, while year-to-date (YTD) performance is 7.56%. BMRN stock has a five-year performance of 17.35%. Its 52-week range is between 70.73 and 97.76, which gives BMRN stock a 52-week price range ratio of 89.90%

BioMarin Pharmaceutical Inc. currently has a PE ratio of 365.70, a price-to-book (PB) ratio of 3.91, a price-to-sale (PS) ratio of 9.41, a price to cashflow ratio of 148.40, a PEG ratio of 2.32, a ROA of 0.90%, a ROC of 1.11% and a ROE of 1.24%. The company’s profit margin is 2.83%, its EBITDA margin is 9.20%, and its revenue ttm is $1.91 Billion , which makes it $10.31 revenue per share.

Of the last four earnings reports from BioMarin Pharmaceutical Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.20 for the next earnings report. BioMarin Pharmaceutical Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for BioMarin Pharmaceutical Inc. is Strong Buy (1.32), with a target price of $111.23, which is +17.05% compared to the current price. The earnings rating for BioMarin Pharmaceutical Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

BioMarin Pharmaceutical Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

BioMarin Pharmaceutical Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 14.57, ATR14 : 2.45, CCI20 : 98.82, Chaikin Money Flow : 0.18, MACD : 3.23, Money Flow Index : 68.74, ROC : 11.32, RSI : 72.42, STOCH (14,3) : 93.73, STOCH RSI : 0.88, UO : 62.34, Williams %R : -6.27), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of BioMarin Pharmaceutical Inc. in the last 12-months were: Brian Mueller (Sold 0 shares of value $-237 335 ), Brian Mueller (Sold 10 837 shares of value $987 412 ), Charles Greg Guyer (Sold 6 205 shares of value $599 155 ), Dennis J. Slamon (Sold 6 296 shares of value $493 178 ), Elaine J. Heron (Sold 0 shares of value $-318 410 ), G. Eric Davis (Sold 0 shares of value $-4 572 497 ), G. Eric Davis (Sold 101 566 shares of value $9 044 118 ), Jean-Jacques Bienaime (Sold 0 shares of value $-4 345 360 ), Jean-Jacques Bienaime (Sold 116 500 shares of value $9 483 282 ), Jeffrey R. Ajer (Sold 16 428 shares of value $1 309 691 ), Richard A. Meier (Sold 0 shares of value $-318 410 ), Richard A. Meier (Sold 3 878 shares of value $318 345 ), V. Bryan Lawlis (Sold 0 shares of value $-318 410 ), V. Bryan Lawlis (Sold 8 500 shares of value $727 898 )